Fermenta Biotech Share Price

BSE
336
+1.00 (0.30%)
FERMENTA • 13 Jun, 2025 | 03:09 PM
BUY

1Y Annualised Return

88.41%

3Y Annualised Return

19.13%

5Y Annualised Return

3.02%

The current prices are delayed, login or Open Demat Account for live prices.

Fermenta Biotech SIP Return Calculator

Over the past

1 year
3 years
5 years

Total Investment of ₹65,00,000

Would have become ₹1,04,54,668 (+60.84%)

Daily SIP of 25,000 would have become 1,04,54,668 in 1 year with a gain of 39,54,668 (+60.84%)

Fermenta Biotech Stock Performance
Today’s Low - High
335.10
338.10
335.10
338.10
52 Week Low - High
163.00
449.00
163.00
449.00

Open

335.10

Prev. Close

335.00

Volume

12,923.00

Total Traded Value

43.69 L

View details of Market Depth
Fermenta Biotech Fundamental

Market Cap (in crs)

995.06

Face Value

5

Turnover (in lacs)

43.69

Key Metrics
Qtr Change %
107.42% Gain from 52W Low
38.6
Dividend yield 1yr %
Below industry Median
0.4

Fermenta Biotech Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Fermenta Biotech Quarterly Revenue

Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
139.85 Cr
156.47 Cr
95.03 Cr
78.13 Cr
97.34 Cr

Fermenta Biotech Yearly Revenue

Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
481.3 Cr
347.47 Cr
357.64 Cr
406.65 Cr
385.54 Cr
305.27 Cr

Fermenta Biotech Quarterly Net Profit/Loss

Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
33.32 Cr
37.89 Cr
11.12 Cr
-5.93 Cr
-7.14 Cr

Fermenta Biotech Yearly Net Profit/Loss

Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
76.4 Cr
-24.01 Cr
-53.55 Cr
15.06 Cr
42.53 Cr
59.52 Cr

Fermenta Biotech shareholding Pattern

Promoter
64.1%
Public
35%
Promoter
62.1%
Public
37%
Promoter
62.1%
Public
36.4%
Promoter
62.1%
Public
36.1%
Promoter
62.1%
Public
36%
Promoter
62.1%
Public
36%

Fermenta Biotech Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
336
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
333.50
10Day EMA
326.90
12Day EMA
324.30
20Day EMA
315.40
26Day EMA
310.30
50Day EMA
301.10
100Day EMA
302.00
200Day EMA
294.40
5Day SMA
334.20
10Day SMA
327.70
20Day SMA
313.50
30Day SMA
299.70
50Day SMA
291.00
100Day SMA
300.60
150Day SMA
325.70
200Day SMA
318.90
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
12923 Rs
12923 Rs
Week Rs
23333 Rs
23333 Rs
Month Rs
16111 Rs
16111 Rs
Resistance & Support
337.10
Pivot
Resistance
First Resistance
339.10
Second Resistance
340.10
Third Resistance
342.10
Support
First Support
336.10
Second support
334.10
Third Support
333.10
Relative Strength Index
72.09
Money Flow Index
91.56
MACD
14.02
MACD Signal
12.07
Average True Range
8.12
Average Directional Index
34.20
Rate of Change (21)
17.09
Rate of Change (125)
-17.54

Fermenta Biotech Latest News

04 JUN 2025 | Wednesday

Fermenta Biotech Ltd - 506414 - Announcement under Regulation 30 (LODR)-Investor Presentation

29 MAY 2025 | Thursday

Fermenta Biotech Ltd - 506414 - Clarification On Record Date

29 MAY 2025 | Thursday

Fermenta Biotech Ltd - 506414 - Announcement under Regulation 30 (LODR)-Newspaper Publication

View More

Fermenta Biotech Company background

Founded in: 1951
Managing director: Prashant Nagre
Fermenta Biotech Limited was formerly incorporated as DupharInterfran Limited in May, 1951. The Company name was changed to DIL Limited in September, 2003 and later on, the name was further changed to Fermenta Biotech Limited on October 17, 2019.The Company is engaged in the business of manufacturing and marketing of chemicals, bulk drugs, enzymes, pharmaceutical formulations and environmental solution products and renting and selling of properties. The Company has strategic investments in subsidiaries primarily dealing in manufacturing and marketing bulk drugs.In the initial years, the company manufactured and sold toothpaste, antiseptic lotion and pharmaceutical specialities on a loanlicence basis. It entered into collaborations with PhilipsDuphar, Amsterdam (Solvay Duphar), and the Crookes Laboratories, London. These collaborators participated in the equity capital of the company to the extent of 25% each.In 1964, Company entered into a collaboration with Solvay Duphar to manufacture vitamin D3. In 1976, it entered into another collaboration with Solvay Duphar to manufacture isoxypurine hydrochloride a vasodilator. In 1976, in compliance with the FERA, the foreign collaborators reduced thier stake to 38.86%.Company came out with a rights issue in May 95 to augment longterm resources and working capital requirements. The company also sold its popular analgesic brand Crocin to Smithkline Beecham Pharmaceuticals. It also sold another OTC brand, LactoCalamine lotion to Nicholas Piramal to concentrate on the core business of ethical drugs.As per the Scheme of Arrangement, the Pharma Division of the Company was transferred to Duphar Pharma India. The Company has made investments in unutilised premises at Thane to create a commercial complex with modern facilities so that substantial portion of it can be let out to earn income. The successful entry of Annual Contract with Solvay Pharmaceuticals B V of Netherlands will definitely establish as a reliable contract research organization for Duphar Interfran Ltd. As mutual consent with Solvay Pharmaceuticals,Netherlands,the company has been permitted to continue with the name DUPHAR for a limited time. It has also been decided to change the name to DIL Limited from DupharInterfran Ltd.With the prior approval from Board the company has acquired 990,000 equity shares of Rs.10 each in Fermenta Biotech Ltd there by increase its holding to 83.71% comprising 16,57,500 equity shares. Subsequent to this FBL will henceforth be a subsidiary of Duphar Interfran Ltd.In 2003, the Company expanded manufacturing capacity with Vitamin D and other products such as Phenyramidol at Kullu. During the year 200910, the Company carried out the Drug Discovery and Development Services through its subsidiaries, Evotec (India) Private Limited and its subsidiary EvotecRSIL Limited up to August 31, 2009. Through the divestment of 70% equity shares by the Company in Evotec (India) Private Limited, Evotec (India) Private Limited and its subsidiary EvotecRSIL Limited ceases to be subsidiaries of the Company with effect from September 01, 2009. New projects were undertaken with Bayer CropSciences, Novartis, Boehringer Ingelheim and Chugai. The Company commissioned a new manufacturing facility at Dahej SEZ, Gujarat during 201011. The Company executed a definitive agreements with a private equity investor in Mauritius, Evolvence India Life Sciences Fund LLC (EILSF) on December 10, 2010 for sale of 1,915,036 equity shares held by Company in FBL to EILSF and issue of an equal number of fresh equity shares by FBL to EILSF, for a total consideration of Rs. 40 crores, which was completed in Jan11. It launched new and improved Penicillin G Acylase catalyst Fermase PA 850 in 2012.Agastya Films LLP and Zela Wellness Private Limited ceased to be joint venture entity and associate company w.e.f. January 01, 2019 and Novemeber 29, 2018 respectively. The Company in FY 201920, launched a new product, fish oil derived cholesterol, for the aquaculture market, it launched a new version of Vitamin D 500 feed grade powder in 2020. During the year 201920, the Scheme of Amalgamation between the Parent i.e. DIL Limited (DIL) and its subsidiary, Fermenta Biotech Limited (FBL) and their respective shareholders became effective from September 26, 2019, with the appointed date as April 01, 2018. On September 5, 2019, the Companys subsidiary viz. Fermenta Biotech GmbH was incorporated in Germany. The Company incorporated a whollyowned subsidiary in the United States of America viz. Fermenta Biotech USA LLC on May 27, 2020. In December 2020, Fermenta Biotech USA LLC, a wholly owned subsidiary of the Company, acquired 52% membership interest in AGD Nutrition, LLC (now known as Fermenta USA, LLC). In FY 202122, the Company launched Vitamin AD2 for oil fortification and developed patented technology for enzymatic synthesis of Molnupiravir.The Company commissioned a a manufacturing facility for Fortified Rice Kernel (FRK) in Pennepalli, Andhra Pradesh in 2022. The Scheme of Amalgamation amongst DVK Investments Private Limited and Aegean Properties Limited and the Company and their respective Shareholders was made effective on May 24, 2023. Post Effective Date, the Company issued and allotted 150,75,318 equity shares of face value of Rs. 5/ each, fully paidup, to the members of DVK Investments Private Limited on June 02, 2023. As per the terms of NCLT Order dated May 8, 2023 regarding Composite Scheme of Amalgamation and Arrangement, the Companys Holding company, DVK Investments Private Limited and the Companys subsidiary, Aegean Properties Limited ceased to exist w.e.f. May 24, 2023.The Company commissioned its Customized Premixing Plant in Kullu, Himachal Pradesh in 2024.

As of 13 Jun, 2025, FERMENTA share price is ₹338.1. The stock opened at ₹335.1 and had closed at ₹335 the previous day. During today’s trading session, FERMENTA share price moved between ₹335.10 and ₹338.10, with an average price for the day of ₹336.50. Over the last 52 weeks, the stock has recorded a low of ₹163.00 and a high of ₹449.00. In terms of performance, FERMENTA share price has declined by 16.2% over the past six months and has increased by 88.41% over the last year.

Read More

Fermenta Biotech FAQs

You can easily buy Fermenta Biotech shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Fermenta Biotech stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

Open Demat Account
+91 -